Navigation Links
21st Century Biochemicals Marks Its Third Consecutive Year on the Inc. 5000
Date:8/30/2010

NEW YORK, Aug. 30 /PRNewswire/ -- 21st Century Biochemicals, Inc. of Marlborough, MA was included on Inc. Magazine's annual ranking of the 5,000 fastest-growing private companies in the country for the third consecutive year.  For 2010, 21st Century Biochemicals was ranked #2626 after being ranked #575 in 2008 and #2116 in 2009. The list is the most comprehensive look at the most important segment of the economy – America's independent-minded entrepreneurs.  Taken as a whole, these companies represent the backbone of the U.S. economy. 

(Logo:  http://photos.prnewswire.com/prnh/20100817/INC5000LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100817/INC5000LOGO)

21st Century Biochemicals, Inc., founded in 2003, manufactures custom made biochemicals and provides analytical services for use in pharmaceutical and biomedical research laboratories around the globe.  Their products are used in research laboratories studying among other things Alzheimer's disease, cancer, and heart disease as well as those labs doing basic research.  According to Dr. Jordan B. Fishman, Founder and CEO of 21st Century Biochemicals, "Making the list three times in a row is really a testament to our employees and their skill, hard work and dedication.  We often hear from our customers at how pleased they are with the technical support they receive as well as our customer service and product quality.  I could not be prouder of the group of professionals we have assembled."   Dr. Fishman added: "Our scientific staff, of which over one-third hold advanced degrees including PhD's in Biochemistry, Immunology, Neuroscience and Cell Biology, interact with our customers on a very high scientific level with the focus on problem solving in areas where we have expertise.   Thus, rather than just being a source of finished goods, we can act as an extension of their laboratory when needed."

"The leaders of the companies on this year's Inc. 5000 have figured out how to grow their businesses during the longest recession since the Great Depression," said Inc. president Bob LaPointe. "The 2010 Inc. 5000 showcases a particularly hardy group of entrepreneurs."  

"There is no doubt that the current economic climate has presented us and really all companies with a much tougher playing field," according to Dr. Fishman. "We have focused on customer service, product quality, and employee retention as the cornerstones that will allow us to get through until the economy picks up steam.  Thankfully our team has stepped up to the plate during this time and has played a major role in our continuing growth.  Our scientific expertise and ability to utilize our knowledge and skills to help our customers achieve their goals has resulted in growing referrals, published papers citing our work, and co-authorships on several scientific papers."

Complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found on http://www.inc.com/5000.

http://www.21stcenturybio.com


'/>"/>
SOURCE 21st Century Biochemicals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Nile Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
3. Anesiva to Present at BioCentury Newsmakers Conference on September 4, 2008
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Synthetic Biology Importance in the 21st Century
6. Agendia to Present at BioCenturys Future Leaders in the Biotech Industry Conference
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
8. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
9. Information warfare in the 21st century: Ideas are sometimes stronger than bombs
10. Pearson Foundation Supports Incoming LSU Biology Students With 21st Century Learning Tools
11. Information warfare in the 21st century: Ideas are sometimes stronger than bombs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):